Is This the Right Way to Play Biotech?
The allure of achieving incredible gains in short time periods has many investors looking to strike it rich picking biotech stocks. But it's also attracted the attention of many fund companies, which are looking to capitalize on the average investor's interest in a more diversified form of biotech exposure. While my personal preference for the longer term investor looking to invest in biotech is to target a basket of stocks, in the following video, I detail one of the popular biotech ETF options that, in my opinion, investors should avoid.
What's inside Supernova?
If you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.
The article Is This the Right Way to Play Biotech? originally appeared on Fool.com.
Brenton Flynn and The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
